Incanthera plc (AQSE:INC), the specialist company focused on innovative technologies in dermatology and oncology, has announced its audited results for the year ended 31 March 2025.
The company is dedicated to identifying and commercialising novel therapeutic and cosmetic applications that are based upon uniquely targeted delivery technologies.
Post-Balance Sheet Highlights
The company officially launched its Skin+CELL luxury skincare line on 11 August 2025, introducing the brand through a dedicated Direct-to-Consumer (DTC) website — www.skinandcell.com. The rollout was supported by a multi-channel DTC marketing campaign, which began on social media and is now expanding into both digital and traditional media platforms.
The Skin+CELL product range currently includes formulations for face, body, and hands, as well as a face serum and eye cream, each designed to deliver high-performance skincare results.
In scientific testing, the company successfully achieved proof of concept for its proprietary Skin+CELL formulation technology, demonstrating that the product provides protective effects against UV-induced damage in human skin cells — a key milestone validating the brand’s scientific foundation.
Financial Highlights
The company recorded its first revenues from Skin+CELL sales within the initial weeks of launch, marking an encouraging start for the new brand.
In June 2025, the company completed an institutional fundraise of £508,000, providing additional capital to support product rollout and marketing initiatives.
Throughout the period, management maintained tight cost controls through a lean operating model, ensuring efficient use of resources and a disciplined financial structure.
The company also continued to safeguard its valuable intellectual property, securing protection for its patents and trademarks across multiple global territories.
Simon Ward, Chief Executive Officer, commented:
“I am immensely proud of our Skin+CELL product range, now available to the world-wide market, and achieving sales, following the launch on 11 August via our dedicated DTC website: www.skinandcell.com. There has been immediate positive feedback from users of our Skin+CELL products, extolling the beneficial impact on their skin tone and appearance and confirming that Skin+CELL will be an integral part of their skin and beauty regimen going forward.
“As the DTC campaign has developed, we have seen good engagement and conversion to sales, increasing in recent weeks. As this gathers further momentum over the next period, we anticipate sales volumes to increase accordingly, and our expectation is to sell the current stock of 100,000 units by 31 March 2026.
“We are also actively exploring additional routes to market to add to the DTC route and are in the active design and development phase of our new range to include SPF concentrations.
“Following on from what has been a truly challenging year, we now look forward with confidence.
“I take this opportunity, on behalf of myself and the team, to thank all our partners, advisors and our very loyal shareholders for their continued unwavering support.”
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply